Meet Vyro: Zika Virus, the enemy that turned hero

Vyro is a biotechnology start-up focused on developing a viral platform based on genetic engineering of the Zika virus. Its goal is to create cancer-killing viruses, also known as “oncolytics,” that are designed to target malignant tumors, including those of the central nervous system (CNS) in adults and children.

The company was founded by Brazilian scientists from the Human Genome and Stem Cell Research Center (HUG-CELL) at the Biosciences Institute of the University of São Paulo. These scientists are now part of the Vyro Biotherapeutics team and are conducting trials based on pioneering research into the oncolytic properties of the Zika Virus (ZIKV).

Find out more about our technology at: https://vyrobio.com/